Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Norian, Lyse A ^a   Kresowik, Timothy P ^a   Rosevear, Henry M ^a   James, Britnie R ^b   Rosean, Timothy R ^a   Lightfoot, Andrew J ^a   Kucaba, Tamara A ^b   Schwarz, Christopher ^a   Weydert, Christine J ^a   Henry, Michael D ^a   Griffith, Thomas S ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CD8 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL INFILTRATION; CELL TRANSPORT; CONTROLLED STUDY; DISEASE DURATION; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; SPLENOMEGALY; THERAPY EFFECT; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CPG ISLAND; FEASIBILITY STUDY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ADENOVIRIDAE; MURINAE; MUS;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD8; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CPG ISLANDS; FEASIBILITY STUDIES; FEMALE; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84856437688     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031085     Document Type: Article

References (53)

1. Patil S, Ishill N, Deluca J, Motzer RJ, (2010) Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer 116: 347-354.
2. McDermott DF, (2009) Immunotherapy of metastatic renal cell carcinoma. Cancer 115: 2298-2305.
3. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, et al. (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11: 1969-1977.
4. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, et al. (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188-1194.
5. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, et al. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696.
6. Rini BI, (2010) New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance. Clin Cancer Res 16: 1348-1354.
7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, et al. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690.
8. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
9. Holoch PA, Griffith TS, (2009) TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625: 63-72.
10. Griffith TS, Stokes B, Kucaba TA, Earel JK Jr, VanOosten RL, et al. (2009) TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 9: 9-19.
11. Abdulghani J, El-Deiry WS, (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14: 1091-1108.
12. Elliott MR, Ravichandran KS, (2010) Clearance of apoptotic cells: implications in health and disease. J Cell Biol 189: 1059-1070.
13. Krieg AM, (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117: 1184-1194.
14. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
15. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, et al. (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31: 520-527.
16. VanOosten RL, Griffith TS, (2007) Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 67: 11980-11990.
17. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K, (2010) Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 30: 575-579.
18. Wang L, Wen W, Yuan J, Helfand B, Li Y, et al. (2010) Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells. Clin Cancer Res 16: 164-173.
19. Shablak A, Hawkins RE, Rothwell DG, Elkord E, (2009) T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res 15: 6503-6510.
20. Westwood JA, Darcy PK, Guru PM, Sharkey J, Pegram HJ, et al. (2010) Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med 8: 42-49.
21. Matin SF, Sharma P, Gill IS, Tannenbaum C, Hobart MG, et al. (2010) Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 183: 333-338.
22. Shvarts O, Janzen N, Lam JS, Leppert JT, Caliliw R, et al. (2006) RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. Urology 68: 1132-1138.
23. Flanigan RC, Campbell SC, Clark JI, Picken MM, (2003) Metastatic renal cell carcinoma. Curr Treat Options Oncol 4: 385-390.
24. Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD, (2007) Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 67: 10445-10454.
25. Drake JM, Gabriel CL, Henry MD, (2005) Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis 22: 674-684.
26. Norian LA, Rodriguez PC, O'Mara LA, Zabaleta J, Ochoa AC, et al. (2009) Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res 69: 3086-3094.
27. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, et al. (2003) Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 19: 9-19.
28. Salup RR, Wiltrout RH, (1986) Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Cancer Res 46: 3358-3363.
29. Yockman JW, Kim WJ, Chang CW, Kim SW, (2007) Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Gene Ther 14: 1399-1405.
30. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, et al. (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100: 649-662.
31. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, et al. (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70: 3526-3536.
32. Rocha FG, Chaves KC, Chammas R, Peron JP, Rizzo LV, et al. (2010) Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. Cancer Immunol Immunother 59: 1357-1365.
33. Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, et al. (2008) Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 181: 346-353.
34. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, et al. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 168: 3484-3492.
35. Clausen BE, Kel JM, (2010) Langerhans cells: critical regulators of skin immunity? Immunol Cell Biol 88: 351-360.
36. Yu P, Lee Y, Wang Y, Liu X, Auh S, et al. (2007) Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179: 1960-1968.
37. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, et al. (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207: 637-650.
38. Lv S, Zhang J, Wu J, Zheng X, Chu Y, et al. (2005) Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol Lett 99: 217-227.
39. Cao Q, Xu W, Wen Z, Xu L, Li K, et al. (2008) An anti-double-stranded DNA monoclonal antibody induced by tumor cell-derived DNA inhibits the growth of tumor in vitro and in vivo via triggering apoptosis. DNA Cell Biol 27: 91-100.
40. Godley PA, Taylor M, (2001) Renal cell carcinoma. Curr Opin Oncol 13: 199-203.
41. Ather MH, Masood N, Siddiqui T, (2010) Current management of advanced and metastatic renal cell carcinoma. Urol J 7: 1-9.
42. Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, et al. (2001) Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype. Cancer Res 61: 6255-6263.
43. Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH, (1990) Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res 50: 5414-5420.
44. Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, et al. (2003) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63: 207-213.
45. Kemp TJ, Kim JS, Crist SA, Griffith TS, (2003) Induction of necrotic tumor cell death by TRAIL/Apo-2L. Apoptosis 8: 587-599.
46. Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, et al. (2009) Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69: 6615-6623.
47. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC, (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13: 721s-726s.
48. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, et al. (2006) Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 107: 46-53.
49. Frankenberger B, Noessner E, Schendel DJ, (2007) Immune suppression in renal cell carcinoma. Semin Cancer Biol 17: 330-343.
50. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, et al. (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65: 3044-3048.
51. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, et al. (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69: 2506-2513.
52. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, et al. (2010) Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 70: 2665-2674.
53. Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, et al. (2010) Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther 17: 465-475.